Preventing the development and progression of diabetic kidney disease: Where do we stand?

Diabetic kidney disease (DKD) is a major factor associated with increased cardiovascular (CV) and all-cause mortality and morbidity in patients with diabetes. Current standard therapy includes intensive management of hyperglycemia and blood pressure control with renin-angiotensin-aldosterone system (RAAS) blockers. Despite the implementation of this strategy, DKD remains the leading cause of end-stage renal disease (ESRD), mainly because of the increasing burden of diabetes mellitus. The aim of this review is to evaluate the available evidence, focusing on the benefit of current treatment in the development and progression of DKD.

• Publication year

  2018

• Venue

  Diabetes & metabolic syndrome

• Publication date

  2018-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.dsx.2018.03.012PMID 29602760
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2018cited by this paper
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

  2017cited by this paper
• A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

  2017cited by this paper
• A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

  2016cited by this paper
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  2016cited by this paper
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

  2016cited by this paper
• Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014.

  2016cited by this paper
• Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

  2016cited by this paper
• Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON

  2016cited by this paper
• Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

  2016cited by this paper
• The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes

  2016cited by this paper
• Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View.

  2015cited by this paper
• Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View

  2015cited by this paper
• Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes.

  2015cited by this paper
• Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents

  2015cited by this paper
• Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes.

  2015cited by this paper
• Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

  2014cited by this paper
• Diabetic kidney disease: a report from an ADA Consensus Conference.

  2014cited by this paper
• 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

  2014cited by this paper
• Diabetic Kidney Disease: A Report From an ADA Consensus Conference

  2014cited by this paper
• Changes in diabetes-related complications in the United States, 1990-2010.

  2014cited by this paper
• Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study.

  2014cited by this paper
• Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction

  2013cited by this paper
• Nonproteinuric diabetic nephropathy: when diabetics don't read the textbook.

  2013cited by this paper
• Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.

  2013cited by this paper
• Kidney disease and increased mortality risk in type 2 diabetes.

  2013cited by this paper
• Combined angiotensin inhibition for the treatment of diabetic nephropathy.

  2013cited by this paper
• Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

  2012cited by this paper
• Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients.

  2012cited by this paper
• Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.

  2011cited by this paper
• Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.

  2011cited by this paper
• Clinical significance of nonalbuminuric renal impairment in type 2 diabetes

  2011cited by this paper
• Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality.

  2011cited by this paper
• Epidemiology of diabetic nephropathy.

  2011cited by this paper
• Temporal trends in the prevalence of diabetic kidney disease in the United States.

  2011cited by this paper
• Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.

  2010cited by this paper
• Global estimates of the prevalence of diabetes for 2010 and 2030.

  2010cited by this paper
• Blood pressure control in chronic kidney disease: is less really more?

  2010cited by this paper
• Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.

  2009cited by this paper
• Lowering blood pressure reduces renal events in type 2 diabetes.

  2009cited by this paper
• Renal and retinal effects of enalapril and losartan in type 1 diabetes.

  2009cited by this paper
• Glucose control and vascular complications in veterans with type 2 diabetes.

  2009cited by this paper
• 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

  2008cited by this paper
• Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

  2008cited by this paper
• Glomerular filtration rate and albuminuria: twin manifestations of nephropathy in diabetes.

  2007cited by this paper
• 2013 ESH/ESC Guidelines for the management of arterial hypertension

  2007cited by this paper
• KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

  2007cited by this paper
• Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.

  2005cited by this paper
• Systematic review on urine albumin testing for early detection of diabetic complications.

  2005cited by this paper
• Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

  2004cited by this paper
• Preventing microalbuminuria in type 2 diabetes.

  2004cited by this paper
• Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively.

  2001cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

  2001cited by this paper
• The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

  2001cited by this paper
• Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.

  2000cited by this paper
• Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

  2000cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

  1998cited by this paper
• The Stages in Diabetic Renal Disease: With Emphasis on the Stage of Incipient Diabetic Nephropathy

  1983cited by this paper

• A pharmacovigilance study of chronic kidney disease in diabetes mellitus patients with statin treatment by using the US Food and Drug Administration adverse event reporting system

  2024cites this paper
• Statin initiation and risk of incident kidney disease in patients with diabetes

  2023cites this paper
• DIFFERENT METABOLIC PATHWAYS IN DIABETIC KIDNEY DISEASE AND RECENT ADVANCES IN SLOWING DISEASE PROGRESSION

  2021cites this paper
• A Network Pharmacology-Based Strategy for Predicting Active Ingredients and Potential Targets of Shuilu Erxian Dan in Treating Diabetic Kidney Disease

  2020cites this paper
• HbA1c and Blood Pressure Levels in Type 2 Diabetes: How Many Patients are on Target?

  2020cites this paper
• Effects of Keluoxin Capsule Combined with Losartan Potassium on Diabetic Kidney Disease with Qi and Yin Deficiency and Blood Stasis Syndrome: Study Protocol for a Randomized Double-Blind Placebo-Controlled Multicenter Clinical Trial

  2020cites this paper
• Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial

  2020cites this paper
• Glycated Hemoglobin and Blood Pressure Levels in Adults With Type 2 Diabetes: How Many Patients Are on Target?

  2020cites this paper
• Diabetic kidney diseases revisited: A new perspective for a new era

  2019cites this paper